These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 12469941)

  • 1. Elevated kallikrein activity in plasma from stable liver transplant recipients.
    Hayashi J; Salomon DR; Hugli TE
    Int Immunopharmacol; 2002 Nov; 2(12):1667-80. PubMed ID: 12469941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.
    Sulikowski T; Bauer BA; Patston PA
    Protein Sci; 2002 Sep; 11(9):2230-6. PubMed ID: 12192078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma C3a and C4a levels in liver transplant recipients: a longitudinal study.
    Pfeifer PH; Brems JJ; Brunson M; Hugli TE
    Immunopharmacology; 2000 Feb; 46(2):163-74. PubMed ID: 10647874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa.
    Tans G; Janssen-Claessen T; Rosing J; Griffin JH
    Eur J Biochem; 1987 May; 164(3):637-42. PubMed ID: 3552674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Use of chromogenic substrates for estimation of indicators of kallikrein-kinin and blood coagulation systems in blood plasma of patients with nephrotic syndrome].
    Baskova IP; Paskhina TS; Poliantseva LR; Iakubovskaia RI; Tiero A
    Vopr Med Khim; 1983; 29(5):96-9. PubMed ID: 6557709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative study of kallikrein-like serine proteinases from rat submandibular glands.
    Bedi GS
    Prep Biochem Biotechnol; 1996 May; 26(2):85-104. PubMed ID: 8784920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Small molecule inhibitors of plasma kallikrein.
    Young WB; Rai R; Shrader WD; Burgess-Henry J; Hu H; Elrod KC; Sprengeler PA; Katz BA; Sukbuntherng J; Mordenti J
    Bioorg Med Chem Lett; 2006 Apr; 16(7):2034-6. PubMed ID: 16413183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variations in the enzymatic properties of human complement subcomponent C1s by treatment with human plasma kallikrein.
    Okada F; Takahashi K; Nagasawa S; Koyama J
    J Biochem; 1987 Oct; 102(4):939-46. PubMed ID: 3325504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of serine proteinases by squash inhibitors.
    Otlewski J; Zbyryt T; Krokoszyńska I; Wilusz T
    Biol Chem Hoppe Seyler; 1990 Jul; 371(7):589-94. PubMed ID: 2145863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The active site of human C4a anaphylatoxin.
    Hugli TE; Kawahara MS; Unson CG; Molinar-Rode R; Erickson BW
    Mol Immunol; 1983 Jun; 20(6):637-45. PubMed ID: 6603573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human plasma alpha 2-macroglobulin. An inhibitor of plasma kallikrein.
    Harpel PC
    J Exp Med; 1970 Aug; 132(2):329-52. PubMed ID: 4101346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serine protease specificity for peptide chromogenic substrates.
    Mattler LE; Bang NU
    Thromb Haemost; 1977 Dec; 38(4):776-92. PubMed ID: 146272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Action of crotalase, an enzyme with thrombin-like and kallikrein-like specificities, on tripeptide nitroanilide derivatives.
    Simmons G; Bundalian M; Theodor I; Martinoli J; Pirkle H
    Thromb Res; 1985 Nov; 40(4):555-61. PubMed ID: 2934864
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for the presence of five distinct proteolytic components in the pituitary multicatalytic proteinase complex. Properties of two components cleaving bonds on the carboxyl side of branched chain and small neutral amino acids.
    Orlowski M; Cardozo C; Michaud C
    Biochemistry; 1993 Feb; 32(6):1563-72. PubMed ID: 8431436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of kallidin-releasing tissue kallikrein inhibitors based on the specificities of the enzyme's binding subsites.
    Portaro FC; Cezari MH; Juliano MA; Juliano L; Walmsley AR; Prado ES
    Biochem J; 1997 Apr; 323 ( Pt 1)(Pt 1):167-71. PubMed ID: 9173877
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of plasma kallikrein selective inhibitors.
    Okada Y; Tsuda Y; Tada M; Wanaka K; Hijikata-Okunomiya A; Okamoto U; Okamoto S
    Biopolymers; 1999; 51(1):41-50. PubMed ID: 10380351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Centrifugal analysis for plasma kallikrein activity, with use of the chromogenic substrate S-2302.
    Ito R; Statland BE
    Clin Chem; 1981 Apr; 27(4):586-93. PubMed ID: 6907061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Separation of plasma thromboplastin antecedent from kallikrein by the plasma 2 -macroglobulin, kallikrein inhibitor.
    Harpel PC
    J Clin Invest; 1971 Oct; 50(10):2084-90. PubMed ID: 5165598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a surface structure in the fourth component of human complement, C4, which becomes hidden upon activation by C1(-)s.
    Maeda S; Takamaru Y; Fukatsu J; Nagasawa S
    Biochem J; 1993 Jan; 289 ( Pt 2)(Pt 2):503-8. PubMed ID: 7678736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Some proteins not belonging to the clotting or to the kallikrein-kinin system altered by kallikrein.
    Péjaudier L; Kichenin V; Audran R; Steinbuch M
    Hoppe Seylers Z Physiol Chem; 1983 Jun; 364(6):651-4. PubMed ID: 6224732
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.